SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. (" ESSA ," or the " Company ") (NASDAQ: EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. (" Xeno "), a non-profit biotechnology company, under which Xeno will acquire (the " Transaction ") all of the issued and outstanding common shares of ESSA (the " Common Shares "), the Company intends to apply to the Supreme Court of British Columbia (the " Court ") on August 5, 2025 for (i) an interim order authorizing the holding of a special meeting to consider and approve the Transaction (the " Interim Order ") and (ii) for an order authorizing the Company to make an initial cash distribution to its shareholders prior to the closing of the Transaction (the " Distribution Order " and together with the Interim Order, the " Orders ").